Data Virtualization Can Deliver ROI of 408% According to New Independent Research Study
1.12.2021 11:00:00 EET | Business Wire | Press release
Denodo, the leader in data virtualization, today revealed the findings of a new Total Economic Impact™ (TEI) study to demonstrate the tangible benefits of data virtualization using the Denodo Platform. The study, commissioned by Denodo and conducted by Forrester Consulting, quantified the financial impact of the solution and found Denodo customers achieved a return on investment of 408% and total economic benefits of a present value up to $6.8 million over three years.
The complete, complimentary study can be found here.
More specifically, the benefits to a blended organization that consists of long term Denodo customers include:
- 83% reduction in time-to-revenue
- 67% reduction in data preparation effort
- 65% decrease in delivery times over ETL
According to the TEI study, “Data fabric technology takes the data virtualization a step further by automating data management functions using artificial intelligence/machine learning (AI/ML) and providing additional semantic capabilities through data catalog, data preparation, and data modeling. This reduces the burden on IT and data engineering teams that traditionally leveraged ETL processes.”
The TEI study is a culmination of Forrester’s multi-step approach to evaluating the financial impact of the Denodo Platform by interviewing several of Denodo's longest standing customers. To better understand the benefits, costs, and risks associated with this investment, Forrester interviewed key decision-makers across four companies in different industries with experience using the Denodo Platform. The highlights from their investments include:
- Decrease in data delivery times over ETL: “Since deploying Denodo, we have gone anywhere from a couple of days or weeks to less than a day to deliver data sets.” - IT Manager, Manufacturing
- Improved operational efficiency enabled with data-driven decision-making: “From the [operations] perspective, being able to provide business users with the capability to start asking and answering questions themselves … it has really given us the ability to see around the corner. There is no way that my team, even if we dropped everything, would have been able to react to a situation like the pandemic as fast as we did without Denodo.” - VP of Data & Analytics, Real Estate
- Improved profit: “Let’s say it took our data science team three months to write this model for a project, and now we can get that down to one week, we are increasing the probability that the project succeeds as opposed to slowing it down and we can release our product sooner. These are multimillion dollar products, so even delaying them one day can be a million dollars or more in missed revenue.” – Director, Enterprise Architecture, Life Sciences Industry
- Reduced legacy integration costs & efficiency gain for data scientists: “In terms of reducing legacy spending, we’re probably saving $400,000 a year. The flip side of that is Denodo has allowed us to do a lot more so now, we’ve grown that footprint and we’ve replaced that $400,000 with a whole bunch of new things we can never do in the old world. More importantly, our data scientists no longer spend 30% of their time on data wrangling and data curation. They can now spend that time on modeling since we can logically model our data within Denodo.” - VP of Data & Analytics, Real Estate
Data virtualization helps organizations access data across disparate sources and deliver a unified view of the data faster, cheaper, and using fewer resources than traditional data integration approaches. Denodo’s logical data fabric approach goes beyond data virtualization, enabling organizations to effectively integrate and manage their data where it lives without replicating it, allowing both technical and non-technical users to quickly answer key business questions using a data-driven approach.
“With retention rates close to 95%, the Denodo Platform goes beyond every other data virtualization solution enabling organizations to connect to all of their data in real time at half the cost of traditional approaches,” said Ravi Shankar, senior vice president and chief marketing officer at Denodo. “We believe this comprehensive Forrester study demonstrates the power and ROI potential organizations can achieve by leveraging the Denodo Platform, as we help bridge the gap between IT and business.”
For more information, download the study here.
Please Tweet: News: @denodo delivers ROI of 408% according to new independent research study @forrester Total Economic Impact™ study showcases the benefits of Denodo’s #datavirtualization solution to create a logical #datafabric and how it enables customers to rapidly increase business agility and performance https://bit.ly/3xCkvZ4
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005060/en/
Contact information
Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
